2025年阿那莫林价格一览

Anamulin is a highly effective drug for the treatment of cancer cachexia. The market prices of its original drug and generic drugs in 2025 will show a certain difference. This article will introduce in detail the prices of the original drug and generic drugs of Anamorelin, and analyze its domestic listing status and medical insurance reimbursement status.

Prices of Anamorelin original drugs and generic drugs in 2025

Due to the influence of factors such as market supply and demand, purchase channels, and regional differences, the actual price may fluctuate, and the price may vary depending on the dosage and purchase channel.

Original drug price

The original drug of Anamorelin is produced by Ono Pharmaceuticals of Japan. It has been widely used in clinical practice due to its remarkable efficacy and safety. The specification of Anamorelin in Japan is 50mg*100 tablets per box, and the price per box is about US$465

Price of generic drugs

The price of Anamorelin generically produced by Lucius in Laos is about US$413 per box, and the specification per box is 50mg*100 tablets. Generic drugs are basically the same as the original drugs in terms of ingredients and efficacy, providing new treatment options for patients with limited economic conditions.

Domestic marketing status of anamorelin

At present, anamorelin is only approved for marketing in Japan, and has also successively obtained marketing approvals in the United States, Europe and other places. In mainland China, anamorelin has not yet been approved for marketing by the National Medical Products Administration. Patients cannot purchase the drug domestically through formal channels.

Although domestic patients cannot purchase Anamorelin directly, some international pharmacies in large hospitals may import the drug through special channels for patients in need. Patients can consult large general hospitals in their city to find out whether relevant drugs are available.

Reimbursement status of Anamorelin by medical insurance

Anamorelin has not yet been included in the medical insurance catalog, and patients need to bear all costs when using this drug. For many patients, this undoubtedly adds to the financial burden.

With the development of medical science and the continuous improvement of medical insurance policies, anamorelin is expected to be included in the medical insurance catalog in the future, thus reducing the financial pressure on patients. Before that happens, patients can talk to their doctor or local health insurance department to see if there are other payment options or assistance policies available.

It should be noted that medical insurance policies vary from region to region, and the medical insurance system in some countries or regions may cover the cost of anamulin, allowing patients to obtain reimbursement. Health insurance systems in other places may not include anamorelin in their reimbursement coverage. Therefore, patients should fully consider local medical insurance policies when choosing treatment options.